Artículos por temáticas

Transdermal, Infusion, and Surgical Therapies and Effect on Sleep Dysfunction in Parkinson's Disease

Popławska-Domaszewicz K, Ahmed R, van Coller R, Ashkan K, Dafsari H, Chen R, Chaudhuri KR.

Sleep Med Clin. 2025 Sep;20(3):407-416. doi: 10.1016/j.jsmc.2025.05.003. Epub 2025 Jun 13.

TDP-43 proteinopathies and neurodegeneration: insights from Caenorhabditis elegans models

Pir GJ, Buddenkotte J, Alam MA, Own A, Eck RJ, Kraemer BC, Mandelkow E, Steinhoff M.

FEBS J. 2025 Sep 2. doi: 10.1111/febs.70239. Online ahead of print.

Rethinking Parkinson's disease therapy: The overlooked role of GPR143 in L-DOPA effects

Aubignat M.

Rev Neurol (Paris). 2025 Sep;181(7):595-596. doi: 10.1016/j.neurol.2025.07.001. Epub 2025 Jul 9.

Expanding our understanding of synucleinopathies: proteinopathy, proteinopenia, and lipidopathy

Flores-León M, Outeiro TF.

FEBS J. 2025 Sep;292(18):4774-4788. doi: 10.1111/febs.70011. Epub 2025 Feb 25.

Exploring the role of HIF-1α in pathogenesis of parkinson's disease and its potential as a therapeutic target

Kaur N, Aran KR.

Mol Biol Rep. 2025 Sep 2;52(1):858. doi: 10.1007/s11033-025-10944-y.

Recent Insights into the Creation of Histone Deacetylase Inhibitors for the Treatment of Human Diseases

Yudaev P, Aleksandrova Y, Neganova M.

Int J Mol Sci. 2025 Sep 4;26(17):8629. doi: 10.3390/ijms26178629.

Cognitive outcomes of infusion therapies in Parkinson's disease: A comprehensive systematic review

Garon M, Scharfenort M, Antonini A, Odin P, Ljung H.

Parkinsonism Relat Disord. 2025 Sep;138:107950. doi: 10.1016/j.parkreldis.2025.107950. Epub 2025 Jul 10.

Are amyloid-based materials conducive to tissue engineering?

Patel K, Maji SK.

Trends Biotechnol. 2025 Sep 19:S0167-7799(25)00345-2. doi: 10.1016/j.tibtech.2025.08.009. Online ahead of print.

A Metacognitive Strategy Intervention for People With Parkinson's Disease: Pilot and Feasibility Trial

Foster ER, Doty T, Campbell MC, Schechtman K, Toglia J.

Am J Occup Ther. 2025 Sep 1;79(5):7905205040. doi: 10.5014/ajot.2025.051200.

Microbiota-Derived Tryptophan Metabolite Indole-3-Propionic Acid-Emerging Role in Neuroprotection

Owe-Larsson M, Drobek D, Iwaniak P, Kloc R, Urbanska EM, Chwil M.

Molecules. 2025 Sep 5;30(17):3628. doi: 10.3390/molecules30173628.

Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease

Kantor B, O'Donovan B, Chiba-Falek O.

Mol Ther Nucleic Acids. 2025 Jul 17;36(3):102635. doi: 10.1016/j.omtn.2025.102635. eCollection 2025 Sep 9.

Application of curcuminoids in inflammatory, neurodegenerative and aging conditions - Pharmacological potential and bioengineering approaches to improve efficiency

Lagoa R, Rajan L, Violante C, Babiaka SB, Marques-da-Silva D, Kapoor B, Reis F, Atanasov AG.

Biotechnol Adv. 2025 Sep;82:108568. doi: 10.1016/j.biotechadv.2025.108568. Epub 2025 Mar 27.

Potential Risk Factors for Psychosis in Parkinson's Disease: A Review of Cohort and Case-Control Studies

Davydow DS, Okun MS, Pontone GM.

J Geriatr Psychiatry Neurol. 2025 Sep;38(5):311-325. doi: 10.1177/08919887251319558. Epub 2025 Feb 10.

Approaches for treating cardiovascular symptoms in Parkinson's disease

Jost WH, Koschel J.

Ther Adv Neurol Disord. 2025 Sep 16;18:17562864251375181. doi: 10.1177/17562864251375181. eCollection 2025.

Effect of a continuous care model-based program on fatigue, self-efficacy, and quality of life in patients with Parkinson's disease: study protocol for a randomized controlled trial

Tadi ME, Abolhassani S, Nazari F, Chitsaz A.

Trials. 2025 Sep 25;26(1):355. doi: 10.1186/s13063-025-09057-5.